Facebook Vice President David Marcus is the face of the company's Libra digital currency, but the original driving force was a 26-year-old female corporate-development...Technologyread more
Amazon's new policy for account suspensions doesn't go far enough to protect sellers from potentially unfair and wrongful suspensions, merchants say.Technologyread more
There is no end in sight to the Boeing 737 Max grounding after two fatal crashes, prompting airlines to rethink their growth plans.Airlinesread more
After a year of flooding, Midwest farmers face a stifling heat wave that's spreading across the U.S.Weather & Natural Disastersread more
On Saturday, Disney's Marvel Studios announced its upcoming slate of superhero films during a panel at San Diego Comic-Con.Entertainmentread more
Moving lots of data to a public cloud over the internet can take months or years. CNBC got an inside look at how AWS transfers data to the cloud for its clients.Technologyread more
A quarter of the S&P 500 companies report earnings next week, and that could buffet the market as investors await the July Fed meeting.Market Insiderread more
Iran's Revolutionary Guard claims a British tanker it still holds, Stena Impero, failed to follow international maritime rules.World Newsread more
"It troubles me that the most important political office in the world is becoming the face of racism and exclusion," Kaeser said in a Twitter post.Politicsread more
Silver's rally could be losing its shine after the precious metal reached its year-to-date high, futures experts warn.Futures Nowread more
Some 40% of Americans would struggle to come up with even $400 to pay for an emergency expense. Just how are so many Americans so short on cash? Blame debt.Personal Financeread more
The major biotech ETF fell to its lows of the day after Democratic presidential hopeful Hillary Clinton said Monday she would take on "price gouging" in the pharmaceutical industry.
A Sunday New York Times article told of a specialty drug that went from $13.50 to $750 per tablet overnight. Responding on Twitter to this piece, Clinton said Monday she will propose a fix to the situation on Tuesday.
The iShares Nasdaq Biotechnology ETF (IBB) was trading down more than 4 percent by early afternoon, taking a visible leg down around the time of the 10:56 a.m. ET tweet by the presidential candidate.
Biotech stocks are among the hottest group of stocks even as the bull market wanes. The ETF is up 27 percent over the last 12 months, compared with a 2 percent decline for the S&P 500 over the same period.
Investors in the biotech sector often feel as though they are immune from the market lows, according Bradd Kern, managing director at Armored Wolf, which is short IBB. Instead, he said, all the hot money in the sector makes it prone to sharp downward turns when confidence is shaken.
"I do think there will be more days like today," Kern said.
Shares of Retrophin, started by Martin Shkreli, traded down more than 11 percent following Clinton's tweet. Shkreli is also the founder and Turing Pharmaceuticals, which was the subject of the Times article.
Shkreli told CNBC's "Power Lunch " that he stands by the increased price of Daraprim, the specialty drug at the center of the aforementioned New York Times article.
"At this price Daraprim is still actually on the low end of what orphan drugs cost and we're certainly not the first company to raise drug prices, " he said.
"We paid a very, very large amount to buy an unprofitable medicine. We can't continue to lose money on the drug at that price so we took it to a price where we can make a comfortable profit but not any kind of ridiculous profit," Shkreli added. "Turing is a very small company. It's a new company and we're not a profitable company, so for us to try and exist and maintain a profit is pretty reasonable."
Still, the pharmaceutical sector may need reforms, Steve Case, chairman and CEO of investment firm Revolution told CNBC.
"A lot of development now is moving offshore that we're at risk of losing our lead in terms of innovation in this space in the United States," he said. "If we can figure out a way to lower the cost of development and expedite the process of getting these things from the labs into the marketplace, I think that will result in better products, better services for more people, better drugs at lower costs."
Correction: An earlier version misstated the time of Clinton's tweet
—CNBC's Evelyn Cheng contributed to this report.